Free shipping on all orders over $ 500

Tarlatamab

Cat. No. M25077
Tarlatamab Structure
Synonym:

AMG-757

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research.

Chemical Information
CAS Number 2307488-83-9
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Daolin Tang, et al. Transl Lung Cancer Res. Tarlatamab: the promising immunotherapy on its way from the lab to the clinic

[2] Salomon Tendler, et al. J Clin Oncol. Tarlatamab: New Star on the Horizon for Small-Cell Lung Cancer?

[3] Luis Paz-Ares, et al. J Clin Oncol. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

[4] Jonathan Chou, et al. Cancer Res. Immunotherapeutic Targeting and PET Imaging of DLL3 in Small-Cell Neuroendocrine Prostate Cancer

[5] Diego Luigi Cortinovis, et al. Front Med (Lausanne). Harnessing DLL3 inhibition: From old promises to new therapeutic horizons

Related Notch Products
Jagged-1 (188-204)

Jagged-1 (188-204) is a fragment of the Jagged-1 (JAG-1) protein with Notch agonist activity.

DAPM

DAPM is a Notch pathway inhibitor with anticancer activity and antiproliferative effects.

Procyanidin B2 3,3'-di-O-gallate

Procyanidin B2, 3,3'-di-O-gallate is an active constituent. Procyanidin B2, 3,3'-di-O-gallate strongly suppresses the constitutive as well as Jagged1 (Notch1 ligand)-induced activated Notch1 pathway.

SAHM1 TFA 

SAHM1 TFA is a Notch pathway inhibitor. SAHM1 TFA stabilizes hydrocarbon-stapled alpha helical peptide. SAHM1 TFA targets the protein-protein interface and prevents Notch complex assembly.

JI051 

JI051 is a stabilizer for the Hes1-PHB2 interaction. JI051 interacts with a cancer-associated protein chaperone prohibitin 2 (PHB2), induces cell-cycle arrest by inhibiting the Notch downstream effector gene Hes1. Anti-cancer activity.

  Catalog
Abmole Inhibitor Catalog




Keywords: Tarlatamab, AMG-757 supplier, Notch, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.